Perspective Therapeutics (CATX) EBT Margin Growth (1y) (2011 - 2023)
Powered by 
Analysis
Perspective Therapeutics (CATX) EBT Margin Growth (1y) (2011 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.88 Bn | 195.89 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 179.94 Bn | 176.76 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 131.92 Bn | 124.07 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.96 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 61.21 Bn | 56.02 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 53.53 Bn | 48.39 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 33.65 Bn | 30.34 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.83 Bn | 30.55 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 29.64 Bn | 29.64 Bn | 1.16 Mn | -801,907.00 |
| 10 | Perspective Therapeutics | 348.68 Mn | 348.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -36,890.00 |
| Jun 30, 2023 | -46,865.00 |
| Mar 31, 2023 | -48,066.00 |
| Sep 30, 2022 | -1,758.00 |
| Jun 30, 2022 | -2,410.00 |
| Mar 31, 2022 | -1,763.00 |
| Dec 31, 2021 | -2,016.00 |
| Sep 30, 2021 | -5,757.00 |
| Jun 30, 2021 | 1,298.00 |
| Mar 31, 2021 | -973.00 |
| Dec 31, 2020 | 387.00 |
| Sep 30, 2020 | 534.00 |
| Jun 30, 2020 | 478.00 |
| Mar 31, 2020 | 3,976.00 |
| Dec 31, 2019 | 3,360.00 |
| Sep 30, 2019 | 6,129.00 |
| Jun 30, 2019 | 9,019.00 |
| Mar 31, 2019 | 2,600.00 |
| Dec 31, 2018 | 2,098.00 |
| Sep 30, 2018 | 3,112.00 |